Extramedullary involvement in acute lymphoblastic leukemia and its relation to therapy

Area of Science:

• Pediatric Oncology
• Hematology
• Leukemia Research

Background:

• Extramedullary involvement (EMI) is a significant factor in acute lymphoblastic leukemia (ALL).
• Understanding the prevalence and impact of EMI is crucial for effective treatment strategies in pediatric ALL.

Purpose of the Study:

• To investigate the incidence of extramedullary involvement in children with acute lymphoblastic leukemia (ALL).
• To determine the correlation between extramedullary involvement and treatment response in pediatric ALL patients.
• To identify specific subtypes and sites commonly affected by extramedullary involvement.

Main Methods:

• Studied 82 children with ALL, divided into untreated (Group I) and treated/remission/relapse (Group II) cohorts.
• Utilized cerebrospinal fluid (CSF) cytology and fine-needle aspiration cytology (FNAC) of testes and lymph nodes.
• Analyzed extramedullary involvement based on FAB subtypes (L1 and L2) and affected sites.

Main Results:

• Extramedullary involvement (EMI) was observed in 48.9% of untreated and 32.4% of treated/relapsed patients.
• FAB-L2 subtype showed higher EMI rates (66.6%) compared to FAB-L1 (34.6%) in untreated patients.
• Lymph nodes were common in Group I, while testes were common in Group II; remission rates were significantly lower in patients with EMI (68.4%) versus without EMI (95.2%).

Conclusions:

• Extramedullary involvement is a prevalent complication in pediatric ALL, affecting nearly half of untreated cases.
• The presence of extramedullary involvement is associated with poorer treatment outcomes and lower remission rates.
• Diagnostic evaluation for extramedullary sites and consideration of subtype are vital for optimizing therapy in pediatric ALL.